Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (2020)
Attributed to:
MICA: The Newcastle Proximity Laboratory
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/bjd.18981
PubMed Identifier: 32124442
Publication URI: http://europepmc.org/abstract/MED/32124442
Type: Journal Article/Review
Volume: 183
Parent Publication: The British journal of dermatology
Issue: 2
ISSN: 0007-0963